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Big data holds great promise in enabling information collected in the clinic to be utilized 18 
for research, policy, and future care in a virtuous cycle. Many institutions are thus attempting 19 
to arrange themselves as “learning health systems” (LHS), defined by the Institute of Medicine 20 
as a healthcare system “in which knowledge generation is so embedded into the core of the 21 
practice of medicine that it is a natural outgrowth and product of the healthcare delivery 22 
process and leads to continual improvement in care.”1 The stakes for high-functioning LHS are 23 
high: $750 billion per year is estimated to be spent on the provision of healthcare that is 24 
“unnecessary, unproven, or wrong.”2 Challenges to data use and translation are particularly 25 
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Current disparate structures for informed consent in clinical care and research pose 30 
major challenges to LHS. Despite scholarly calls for integration of these two pillars of the 31 
healthcare enterprise, recent regulatory revision and guidance on the topic has not been as 32 
flexible as some LHS advocates had hoped. In addition to streamlining regulatory burden, 33 
cultivating the transition of patients to participants to big data to clinical knowledge will not 34 
only require thoughtful normative frameworks but empirical validity with explicit emphasis on 35 
patient perspectives. There is still much work to be done to reframe and advance this debate. 36 
 37 
Our current health system is founded in an assumption that research must be separated 38 
from clinical care because researchers work in pursuit of generalizable knowledge—as opposed 39 
to the best interests of the patient—and, as such, research participants require additional 40 
protections. Certainly, there are many egregious cases of inappropriate conduct prior to the 41 
enactment of regulatory protections in the 1980s where this caution proved warranted.4 But we 42 
have since moved to a system where participants are protected so zealously from unnecessary 43 
risk in research that it may in fact be compounding unnecessary risk in clinical care—for 44 
example, in situations where researchers cannot adequately compare two standard of care 45 
interventions due to regulatory burden. While there are certainly some types of trial designs 46 
that warrant heightened scrutiny, there is irony in the tension between providing the best 47 
clinical care and being able to study what that standard should actually be.  This tension can 48 
lead to both over-reliance on regulatory exceptions that are poorly understood5 and a lack of 49 
transparency regarding learning activities.2 All the while, empirical evidence suggests that many 50 
patients expect some form of consent for research, and are even uncomfortable with 51 
deidentified research in some circumstances.6
 53 
  52 
It is thus complex to establish best practices for the ethics and regulation of LHS. The 54 
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learning as a bedrock ethical obligation for researchers, clinicians, and patients alike.5 Under 56 
this framework, practitioners and institutions would adopt a duty to “feed information into the 57 
system that increases our knowledge.”5 Patients would also have a duty to contribute their own 58 
experience and information to research relative to the burden such learning would impose. 59 
Under this paradigm, contributing deidentified medical records for review or providing 60 
interviews to improve the healthcare experience would likely be considered ethically obligatory 61 
for patients, whereas being randomized to a clinical trial of a new drug would not.5 Recognizing 62 
a duty to contribute to learning would also, Faden et al. argue, transform the informed consent 63 
process in some cases. If a learning activity might “have a negative impact on the quality of care 64 
or impose burdens above and beyond what they would otherwise experience,” informed 65 
consent would be sought. But if the learning is perceived to have little effect on interests or 66 
rights of patients, such as aggregate big data work, it might not.5
 68 
  67 
Some scholars have seconded this reconsideration of consent practices in particular for 69 
low-risk, low burden, research on medical practice (an integral component of a LHS).6 But 70 
others have critiqued this assumption of participating in an LHS without specific consent as—at 71 
least as of yet—ethically unfounded.8 In addition, recognition of such a duty to contribute to 72 
learning runs counter to past empirical research indicating that patients generally do not 73 




The transition to a functioning LHS will thus also have to come to terms with under what 76 
circumstances informed consent will be required, and under what circumstances it will be 77 
assumed that engagement in a LHS is adequate if there is notice that such learning will occur. 78 
Some have suggested that such notice must involve explaining not only that the patient has 79 
entered a LHS, but also where to access more information and how to voice concerns.10
 84 
 But 80 
these lines should not and will not be entirely up to the administrators, clinicians, researchers, 81 
and ethicists: both patients—and the regulators who protect them from becoming unwitting 82 
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One of the most important components of the transition to LHS from a patient 85 
perspective will be for such systems to engage in conscious efforts to build and maintain their 86 
trust.6,11 But normative proposals have not yet fully dispensed with how to address the 87 
increasingly blurry distinction between clinician and researcher while still maintaining the trust 88 
of the patients served.12 Empirical work has found that in addition to trust, patient “awareness, 89 
knowledge, and understanding of health information technology,” as well as attitudes toward 90 
health information privacy and electronic medical records, all influence this delicate balance.11 91 
Sociodemographic factors such as education level and age also appear important.11 Survey 92 
participants have expressed expectations for formal opt-in consent,11 and a substantial minority 93 
(35%) have reported they believe it is necessary to obtain consent each time for secondary 94 
research use of data.6
 98 
 Whether these attitudes evolve after greater understanding, 95 
deliberation, or cultural transformation of the broader healthcare environment remains to be 96 
seen. 97 
From a regulatory perspective, further challenges arise due to inconsistent regulations 99 
or interpretation thereof across federal agencies and offices governing research. One study of 100 
IRB members found that members struggle to categorize research on medical practice as 101 
needing or not needing IRB review and oversight: “They characterized the central challenge as a 102 
balancing act, between, on the one hand, making information fully transparent to patients and 103 
providing adequate oversight, and on the other hand, avoiding a chilling effect on the research 104 




An excellent case-in-point is the recent regulatory debate over revisions to the 108 
“Common Rule” governing federally funded human subjects research. Over six years (2011-109 
2017) stakeholders—including regulators, researchers, institutions, and advocacy 110 
organizations—vigorously debated whether to change the regulations to require informed 111 
consent for research with all human biospecimens (collected in the clinic or research 112 
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identified specimens (as well as data), but concerns had been raised—notably during public 114 
response to  the popular 2010 book, The Immortal Life of Henrietta Lacks15—that research on 115 
any type of biospecimen without consent was disrespectful of the autonomy of the person 116 
from whom the sample was derived. Ultimately, regulators decided not to require informed 117 
consent for deidentified research for human biospecimens, but will revisit how they define 118 
these terms periodically going forward.
 120 
14  119 
However, the revisions did create new categories of exemptions from regulatory 121 
consent and review requirements for the storage or maintenance and secondary research use 122 
of identifiable private information and biospecimens. Previously, full IRB review and specific 123 
informed consent (or a waiver) had to be obtained for all research with identifiable data or 124 
specimens. But going forward, researchers will only have to obtain “limited IRB review” and 125 
broad consent from donors in this situation.16 Theoretically, these exemptions will make some 126 
LHS activities easier to accomplish because practitioners can secure limited review and broad 127 
consent when a patient enters the system, which will then follow their data and specimens 128 
through any number of secondary research protocol. Being able to keep these data and 129 
specimens identified will also enable the continued collection of clinical correlates after initial 130 
donation. Some LHS advocates had also supported an exclusion from the regulations for some 131 
quality assurance and quality improvement activities—but regulators declined to offer a 132 




Thus, while some progress has recently been made, a gap still exists between the 136 
theoretical ideal and pragmatic and regulatory reality regarding informed consent for a LHS: 137 
who must request it, what types of learning require it, where waiver is appropriate, when we 138 
still need it, and how to administer such a system. To close this gap will not only require the 139 
commitment of healthcare professionals but the input of patients and willingness of regulators. 140 
We have yet to fully achieve the optimal level of engagement needed to translate clinical 141 
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 143 
Faden et al. called for a new ethical balancing of priorities based on invasiveness of 144 
research.5 Empiric scholars have noted that while regulators often focus on the sensitivity of 145 
data, type of use is more often cited as a concern amongst providers and patients and might 146 
therefore be a better metric for regulatory involvement. 17,18
 150 
 Future empirical and normative 147 
work is still clearly required to transition from a healthcare system supported by separate 148 
pillars of research and clinical care to one where learning from big data is foundational. 149 
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